We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Trade Group Cautions on Adding Payment Data to Medicare Site

Trade Group Cautions on Adding Payment Data to Medicare Site

September 11, 2015

AdvaMed is urging the Centers for Medicare & Medicaid Services not to include data on device company payments to clinicians on its Physician Compare website.

The appeal comes in response to a comprehensive proposed rule revising the physician fee schedule and other Medicare Part B payment policies. As part of the proposed rule, CMS sought stakeholder feedback on including Open Payments data on Physician Compare.

As part of a package of comments, AdvaMed says, CMS should include only general information or reference the Open Payments website on Physician Compare, which helps patients choose doctors who are enrolled in Medicare.

“[I]ncluding on Physician Compare a reference or link to the Open Payments website, as opposed to Open Payments data, is appropriate because the Physician Compare website and the Open Payments website are separate programs created for different purposes.

“As a result, information and data from the two websites cannot and should not be combined after the fact,” the group says.

In the proposed rule, CMS notes that consumers have indicated that “this level of transparency is important to them and access to this information on Physician Compare increases their ability to find and evaluate the information.”

If CMS ultimately decides to include payment data on eligible providers’ profile pages, it should ensure the data match what’s on the Open Payments website, particularly since there is a disputes and corrections policy to fix inaccuracies, AdvaMed says.

More than 2,000 Comments

The trade group was one of nearly 2,300 stakeholders across a range of industries to comment on the proposed rule.

The Medical Imaging & Technology Alliance expressed support for a plan to develop appropriate use criteria to specify when a diagnostic imaging service should be used, but said industry should have a seat at the table in AUC development.

To ensure transparency, the group says identities of devicemakers that work with provider-led entities should be made public.

CMS defines PLE as “a national professional medical specialty society or an organization that is comprised primarily of providers and is actively engaged in the practice and delivery of healthcare.”

The association says in its comments that it agrees with this definition.

AdvaMed’s comments are available at: www.fdanews.com/091515-advamed.pdf. MITA’s may be found at: www.fdanews.com/091515-MITA.pdf. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing